Cancer cells activate de novo fatty acid synthesis to provide essential structural components and substrates for the generation of signalling molecules.
Transcriptional regulators of lipid biosynthesis are downstream targets of oncogenes and tumour suppressor pathways.
Cancer cells can induce lipid uptake to respond to changes in environmental conditions.
Dependence of cancer cells on lipid synthesis or uptake may be defined by the conditions of the tumour microenvironment.
Lipid synthesis contributes to cellular processes linked to tumour progression.
Multiple lipid metabolism enzymes have been investigated as potential targets for cancer therapy.
Lipid metabolism, in particular the synthesis of fatty acids (FAs), is an essential cellular process that converts nutrients into metabolic intermediates for membrane biosynthesis, energy storage and the generation of signalling molecules. This Review explores how different aspects of FA synthesis promote tumorigenesis and tumour progression. FA synthesis has received substantial attention as a potential target for cancer therapy, but strategies to target this process have not yet translated into clinical practice. Furthermore, efforts to target this pathway must consider the influence of the tumour microenvironment.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Warburg, O., Posener, K. & Negelein, E. Über den Stoffwechsel der Carcinomzelle. Biochem. Zeitschr. 152, 309–344 (in German) (1924).
Medes, G., Thomas, A. & Weinhouse, S. Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res. 13, 27–29 (1953). This study was the first to determine lipid synthesis in neoplastic tissues.
Ookhtens, M., Kannan, R., Lyon, I. & Baker, N. Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor. Am. J. Physiol. 247, R146–R153 (1984).
Kuhajda, F. P. et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc. Natl Acad. Sci. USA 91, 6379–6383 (1994).
Santos, C. R. & Schulze, A. Lipid metabolism in cancer. FEBS J. 279, 2610–2623 (2012).
Currie, E., Schulze, A., Zechner, R., Walther, T. C. & Farese, R. V. Jr. Cellular fatty acid metabolism and cancer. Cell Metab. 18, 153–161 (2013).
Shevchenko, A. & Simons, K. Lipidomics: coming to grips with lipid diversity. Nat. Rev. Mol. Cell Biol. 11, 593–598 (2010).
Menendez, J. A. & Lupu, R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 7, 763–777 (2007).
Kusakabe, T. et al. Fatty acid synthase is expressed mainly in adult hormone-sensitive cells or cells with high lipid metabolism and in proliferating fetal cells. J. Histochem. Cytochem. 48, 613–622 (2000).
Cai, Y. et al. Loss of chromosome 8p governs tumor progression and drug response by altering lipid metabolism. Cancer Cell 29, 751–766 (2016).
Zaidi, N., Swinnen, J. V. & Smans, K. ATP-citrate lyase: a key player in cancer metabolism. Cancer Res. 72, 3709–3714 (2012).
Brownsey, R. W., Boone, A. N., Elliott, J. E., Kulpa, J. E. & Lee, W. M. Regulation of acetyl-CoA carboxylase. Biochem. Soc. Trans. 34, 223–227 (2006).
Maier, T., Leibundgut, M. & Ban, N. The crystal structure of a mammalian fatty acid synthase. Science 321, 1315–1322 (2008).
Jakobsson, A., Westerberg, R. & Jacobsson, A. Fatty acid elongases in mammals: their regulation and roles in metabolism. Prog. Lipid Res. 45, 237–249 (2006).
Igal, R. A. Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell proliferation, programmed cell death and transformation to cancer. Carcinogenesis 31, 1509–1515 (2010).
Horton, J. D. Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis. Biochem. Soc. Trans. 30, 1091–1095 (2002).
Amemiya-Kudo, M. et al. Transcriptional activities of nuclear SREBP-1a, -1c, and -2 to different target promoters of lipogenic and cholesterogenic genes. J. Lipid Res. 43, 1220–1235 (2002).
Mullen, P. J., Yu, R., Longo, J., Archer, M. C. & Penn, L. Z. The interplay between cell signaling and the mevalonate pathway in cancer. Nat. Rev. Cancer https://dx.doi.org/10.1038/nrc.2016.76 (2016).
Shimano, H. et al. Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes. J. Biol. Chem. 274, 35832–35839 (1999).
Shechter, I., Dai, P., Huo, L. & Guan, G. IDH1 gene transcription is sterol regulated and activated by SREBP-1a and SREBP-2 in human hepatoma HepG2 cells: evidence that IDH1 may regulate lipogenesis in hepatic cells. J. Lipid Res. 44, 2169–2180 (2003).
Duvel, K. et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 39, 171–183 (2010). This study identified SREBP as a major component of the gene regulatory network downstream of mTORC1.
Walker, A. K. et al. A conserved SREBP-1/Phosphatidylcholine feedback circuit regulates lipogenesis in metazoans. Cell 147, 840–852 (2011).
Nohturfft, A. & Zhang, S. C. Coordination of lipid metabolism in membrane biogenesis. Annu. Rev. Cell Dev. Biol. 25, 539–566 (2009).
Brown, M. S. & Goldstein, J. L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89, 331–340 (1997).
Espenshade, P. J. & Hughes, A. L. Regulation of sterol synthesis in eukaryotes. Annu. Rev. Genet. 41, 401–427 (2007).
Horton, J. D., Goldstein, J. L. & Brown, M. S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125–1131 (2002).
Fleischmann, M. & Iynedjian, P. B. Regulation of sterol regulatory-element binding protein 1 gene expression in liver: role of insulin and protein kinase B/cAkt. Biochem. J. 349, 13–17 (2000).
Yang, Y. A., Han, W. F., Morin, P. J., Chrest, F. J. & Pizer, E. S. Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp. Cell Res. 279, 80–90 (2002).
Porstmann, T. et al. PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 24, 6465–6481 (2005).
Porstmann, T. et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 8, 224–236 (2008). This study was the first to demonstrate that SREBP is regulated by mTORC1 and contributes to cell growth.
Finck, B. N. et al. Lipin 1 is an inducible amplifier of the hepatic PGC-1α/PPARα regulatory pathway. Cell Metab. 4, 199–210 (2006).
Peterson, T. R. et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 146, 408–420 (2011). This study implicated LPIN1 in the regulation of SREBP by mTORC1.
Han, J. et al. The CREB coactivator CRTC2 controls hepatic lipid metabolism by regulating SREBP1. Nature 524, 243–246 (2015). This study showed regulation of SREBP1 processing by mTORC1 through phosphorylation of CRTC2.
Welcker, M. & Clurman, B. E. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. Cancer 8, 83–93 (2008).
Sundqvist, A. et al. Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). Cell Metab. 1, 379–391 (2005).
Bengoechea-Alonso, M. T. & Ericsson, J. A phosphorylation cascade controls the degradation of active SREBP1. J. Biol. Chem. 284, 5885–5895 (2009). References 35 and 36 demonstrated that the stability of mature SREBP is controlled by GSK3β-dependent phosphorylation and ubiquitination by the FBXW7 ubiquitin ligase.
Dang, C. V. MYC on the path to cancer. Cell 149, 22–35 (2012).
Tong, X., Zhao, F., Mancuso, A., Gruber, J. J. & Thompson, C. B. The glucose-responsive transcription factor ChREBP contributes to glucose-dependent anabolic synthesis and cell proliferation. Proc. Natl Acad. Sci. USA 106, 21660–21665 (2009).
Carroll, P. A. et al. Deregulated myc requires MondoA/Mlx for metabolic reprogramming and tumorigenesis. Cancer Cell 27, 271–285 (2015). This study demonstrated that induction of lipid synthesis by MondoA is essential for MYC transformed cells. The effect of MondoA repression was rescued by oleic acid, confirming the importance of monounsaturated FAs for cancer cells.
Ventura, R. et al. Inhibition of de novo palmitate synthesis by fatty acid synthase induces apoptosis in tumor cells by remodeling cell membranes, inhibiting signaling pathways, and reprogramming gene expression. EBioMedicine 2, 806–822 (2015).
Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L. & Denko, N. C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 3, 187–197 (2006).
Wise, D. R. et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability. Proc. Natl Acad. Sci. USA 108, 19611–19616 (2011).
Metallo, C. M. et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481, 380–384 (2011).
Kamphorst, J. J., Chung, M. K., Fan, J. & Rabinowitz, J. D. Quantitative analysis of acetyl-CoA production in hypoxic cancer cells reveals substantial contribution from acetate. Cancer Metab. 2, 23 (2014).
Kamphorst, J. J. et al. Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc. Natl Acad. Sci. USA 110, 8882–8887 (2013). This study showed that hypoxic or KRAS-transformed cells selectively take up monounsaturated lipids.
Bensaad, K. et al. Fatty acid uptake and lipid storage induced by HIF-1α contribute to cell growth and survival after hypoxia-reoxygenation. Cell Rep. 9, 349–365 (2014). This study implicated lipid storage by hypoxic cells in energy provision after reoxygenation.
Michiels, C., Tellier, C. & Feron, O. Cycling hypoxia: a key feature of the tumor microenvironment. Biochim. Biophys. Acta 1866, 76–86 (2016).
Yasui, H. et al. Low-field magnetic resonance imaging to visualize chronic and cycling hypoxia in tumor-bearing mice. Cancer Res. 70, 6427–6436 (2010).
Gatenby, R. A. & Gillies, R. J. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4, 891–899 (2004).
Yue, S. et al. Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell Metab. 19, 393–406 (2014). This study connected cholesterol esterification to maintain SREBP activity with aggressive behaviour of prostate cancers.
Li, J. et al. Altered metabolic responses to intermittent hypoxia in mice with partial deficiency of hypoxia-inducible factor-1α. Physiol. Genom. 25, 450–457 (2006).
Lewis, C. A. et al. SREBP maintains lipid biosynthesis and viability of cancer cells under lipid- and oxygen-deprived conditions and defines a gene signature associated with poor survival in glioblastoma multiforme. Oncogene 43, 5128–5140 (2015).
Tosi, F., Sartori, F., Guarini, P., Olivieri, O. & Martinelli, N. Delta-5 and delta-6 desaturases: crucial enzymes in polyunsaturated fatty acid-related pathways with pleiotropic influences in health and disease. Adv. Exp. Med. Biol. 824, 61–81 (2014).
Wymann, M. P. & Schneiter, R. Lipid signalling in disease. Nat. Rev. Mol. Cell Biol. 9, 162–176 (2008).
Argiles, J. M., Busquets, S., Stemmler, B. & Lopez-Soriano, F. J. Cancer cachexia: understanding the molecular basis. Nat. Rev. Cancer 14, 754–762 (2014).
Sonveaux, P. et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest. 118, 3930–3942 (2008).
Romero, I. L., Mukherjee, A., Kenny, H. A., Litchfield, L. M. & Lengyel, E. Molecular pathways: trafficking of metabolic resources in the tumor microenvironment. Clin. Cancer Res. 21, 680–686 (2015).
Nieman, K. M. et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 17, 1498–1503 (2011). This study provided an elegant example of metabolic symbiosis of cancer cells and adipocytes.
Ye, H. et al. Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche. Cell Stem Cell 19, 23–37 (2016).
Caiado, F., Silva-Santos, B. & Norell, H. Intra-tumour heterogeneity - going beyond genetics. FEBS J. 283, 2245–2258 (2016).
Hatzivassiliou, G. et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8, 311–321 (2005).
Schug, Z. T. & Gottlieb, E. Cardiolipin acts as a mitochondrial signalling platform to launch apoptosis. Biochim. Biophys. Acta 1788, 2022–2031 (2009).
Chicco, A. J. & Sparagna, G. C. Role of cardiolipin alterations in mitochondrial dysfunction and disease. Am. J. Physiol. Cell Physiol. 292, C33–44 (2007).
Kiebish, M. A., Han, X., Cheng, H., Chuang, J. H. & Seyfried, T. N. Cardiolipin and electron transport chain abnormalities in mouse brain tumor mitochondria: lipidomic evidence supporting the Warburg theory of cancer. J. Lipid Res. 49, 2545–2556 (2008).
Warburg, O. On the origin of cancer cells. Science 123, 309–314 (1956).
Wallace, D. C. Mitochondria and cancer. Nat. Rev. Cancer 12, 685–698 (2012).
Mashima, T. et al. p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target. J. Natl Cancer Inst. 97, 765–777 (2005).
Potze, L. et al. Betulinic acid induces a novel cell death pathway that depends on cardiolipin modification. Oncogene 35, 427–437 (2015).
Peck, B. et al. Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments. Cancer Metab. 4, 6 (2016). This study analysed the effect of SCD inhibition on lipid composition and survival in cancer cells. It also demonstrated that SCD silencing efficiently blocks growth of prostate cancer orthografts.
Schepers, A. & Clevers, H. Wnt signaling, stem cells, and cancer of the gastrointestinal tract. Cold Spring Harb. Perspect. Biol. 4, a007989 (2012).
Nile, A. H. & Hannoush, R. N. Fatty acylation of Wnt proteins. Nat. Chem. Biol. 12, 60–69 (2016).
Proffitt, K. D. et al. Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer. Cancer Res. 73, 502–507 (2013).
Liu, J. et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc. Natl Acad. Sci. USA 110, 20224–20229 (2013).
Rios-Esteves, J. & Resh, M. D. Stearoyl CoA desaturase is required to produce active, lipid-modified Wnt proteins. Cell Rep. 4, 1072–1081 (2013).
Kim, H. et al. Unsaturated fatty acids stimulate tumor growth through stabilization of β-catenin. Cell Rep. 13, 496–503 (2015).
Anastas, J. N. & Moon, R. T. WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer 13, 11–26 (2013).
Levental, I., Grzybek, M. & Simons, K. Greasing their way: lipid modifications determine protein association with membrane rafts. Biochemistry 49, 6305–6316 (2010).
Pyne, N. J. & Pyne, S. Sphingosine 1-phosphate and cancer. Nat. Rev. Cancer 10, 489–503 (2010).
Park, J. B. et al. Phospholipase signalling networks in cancer. Nat. Rev. Cancer 12, 782–792 (2012).
Griner, E. M. & Kazanietz, M. G. Protein kinase C and other diacylglycerol effectors in cancer. Nat. Rev. Cancer 7, 281–294 (2007).
Vanhaesebroeck, B., Stephens, L. & Hawkins, P. PI3K signalling: the path to discovery and understanding. Nat. Rev. Mol. Cell Biol. 13, 195–203 (2012).
Muinonen-Martin, A. J. et al. Melanoma cells break down LPA to establish local gradients that drive chemotactic dispersal. PLoS Biol. 12, e1001966 (2014).
Choi, J. W. et al. LPA receptors: subtypes and biological actions. Annu. Rev. Pharmacol. Toxicol. 50, 157–186 (2010).
Bandoh, K. et al. Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett. 478, 159–165 (2000).
Chan, L. C. et al. LPA3 receptor mediates chemotaxis of immature murine dendritic cells to unsaturated lysophosphatidic acid (LPA). J. Leukoc. Biol. 82, 1193–1200 (2007).
Goto, T. et al. The expression profile of phosphatidylinositol in high spatial resolution imaging mass spectrometry as a potential biomarker for prostate cancer. PLoS ONE 9, e90242 (2014).
Louie, S. M., Roberts, L. S., Mulvihill, M. M., Luo, K. & Nomura, D. K. Cancer cells incorporate and remodel exogenous palmitate into structural and oncogenic signaling lipids. Biochim. Biophys. Acta 1831, 1566–1572 (2013).
Hilvo, M. et al. Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res. 71, 3236–3245 (2011).
Rysman, E. et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 70, 8117–8126 (2010).
Wang, D. & Dubois, R. N. Eicosanoids and cancer. Nat. Rev. Cancer 10, 181–193 (2010).
Pan, Y. et al. Deletion of cyclooxygenase-2 inhibits K-ras-induced lung carcinogenesis. Oncotarget 6, 38816–38826 (2015).
Howe, L. R. et al. HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res. 65, 10113–10119 (2005).
Sonoshita, M. et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in ApcΔ 716 knockout mice. Nat. Med. 7, 1048–1051 (2001).
Wang, D., Buchanan, F. G., Wang, H., Dey, S. K. & DuBois, R. N. Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res. 65, 1822–1829 (2005).
Castellone, M. D., Teramoto, H., Williams, B. O., Druey, K. M. & Gutkind, J. S. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-β-catenin signaling axis. Science 310, 1504–1510 (2005).
Zelenay, S. et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162, 1257–1270 (2015). This study demonstrated the role of prostaglandin synthesis in the suppression of myeloid cell activation and immune evasion in melanoma.
De Craene, B. & Berx, G. Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer 13, 97–110 (2013).
Vo, B. T. et al. TGF-β effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway. Endocrinology 154, 1768–1779 (2013).
Jiang, L. et al. Metabolic reprogramming during TGFβ1-induced epithelial-to-mesenchymal transition. Oncogene 34, 3908–3916 (2015).
Nath, A., Li, I., Roberts, L. R. & Chan, C. Elevated free fatty acid uptake via CD36 promotes epithelial-mesenchymal transition in hepatocellular carcinoma. Sci. Rep. 5, 14752 (2015).
Rahaman, S. O. et al. A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metab. 4, 211–221 (2006).
Zhao, W. et al. Candidate anti-metastasis drugs suppress the metastatic capacity of breast cancer cells by reducing membrane fluidity. Cancer Res. 76, 2037–2049 (2016).
Folkman, J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29, 15–18 (2002).
Kazlauskas, A. Lysophosphatidic acid contributes to angiogenic homeostasis. Exp. Cell Res. 333, 166–170 (2015).
Mendelson, K., Evans, T. & Hla, T. Sphingosine 1-phosphate signalling. Development 141, 5–9 (2014).
Schoors, S. et al. Fatty acid carbon is essential for dNTP synthesis in endothelial cells. Nature 520, 192–197 (2015).
Forootan, F. S. et al. Fatty acid activated PPARγ promotes tumorigenicity of prostate cancer cells by up regulating VEGF via PPAR responsive elements of the promoter. Oncotarget 7, 9322–9339 (2016).
Teng, M. W., Galon, J., Fridman, W. H. & Smyth, M. J. From mice to humans: developments in cancer immunoediting. J. Clin. Invest. 125, 3338–3346 (2015).
Kalinski, P. Regulation of immune responses by prostaglandin E2. J. Immunol. 188, 21–28 (2012).
Luan, B. et al. CREB pathway links PGE2 signaling with macrophage polarization. Proc. Natl Acad. Sci. USA 112, 15642–15647 (2015).
Chang, C. H. et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162, 1229–1241 (2015). This study provided evidence of the competition between cancer cells and immune cells for nutrients within the tumour microenvironment.
Wang, R. & Green, D. R. Metabolic checkpoints in activated T cells. Nat. Immunol. 13, 907–915 (2012).
Baginska, J. et al. The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Front. Immunol. 4, 490 (2013).
Kleinfeld, A. M. & Okada, C. Free fatty acid release from human breast cancer tissue inhibits cytotoxic T-lymphocyte-mediated killing. J. Lipid Res. 46, 1983–1990 (2005).
Ma, C. et al. NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis. Nature 531, 253–257 (2016).
Kinlaw, W. B., Baures, P. W., Lupien, L. E., Davis, W. L. & Kuemmerle, N. B. Fatty acids and breast cancer: make them on site or have them delivered. J. Cell. Physiol. 231, 2128–2141 (2016).
Flavin, R., Zadra, G. & Loda, M. Metabolic alterations and targeted therapies in prostate cancer. J. Pathol. 223, 283–294 (2011).
Pizer, E. S. et al. Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res. 56, 1189–1193 (1996).
Pizer, E. S. et al. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res. 60, 213–218 (2000).
Menendez, J. A. et al. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc. Natl Acad. Sci. USA 101, 10715–10720 (2004).
Pizer, E. S., Chrest, F. J., DiGiuseppe, J. A. & Han, W. F. Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines. Cancer Res. 58, 4611–4615 (1998).
Li, J. N. et al. Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Res. 61, 1493–1499 (2001).
Zhou, W. et al. Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. Cancer Res. 63, 7330–7337 (2003).
Menendez, J. A., Vellon, L., Colomer, R. & Lupu, R. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. Int. J. Cancer 115, 19–35 (2005).
Gabrielson, E. W., Pinn, M. L., Testa, J. R. & Kuhajda, F. P. Increased fatty acid synthase is a therapeutic target in mesothelioma. Clin. Cancer Res. 7, 153–157 (2001).
Horiguchi, A. et al. Pharmacological inhibitor of fatty acid synthase suppresses growth and invasiveness of renal cancer cells. J. Urol. 180, 729–736 (2008).
Relat, J. et al. Different fatty acid metabolism effects of (-)-epigallocatechin-3-gallate and C75 in adenocarcinoma lung cancer. BMC Cancer 12, 280 (2012).
Chen, H. W., Chang, Y. F., Chuang, H. Y., Tai, W. T. & Hwang, J. J. Targeted therapy with fatty acid synthase inhibitors in a human prostate carcinoma LNCaP/tk-luc-bearing animal model. Prostate Cancer Prostat. Dis. 15, 260–264 (2012).
Alli, P. M., Pinn, M. L., Jaffee, E. M., McFadden, J. M. & Kuhajda, F. P. Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. Oncogene 24, 39–46 (2005).
Wang, X. & Tian, W. Green tea epigallocatechin gallate: a natural inhibitor of fatty-acid synthase. Biochem. Biophys. Res. Commun. 288, 1200–1206 (2001).
Loftus, T. M. et al. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 288, 2379–2381 (2000).
Shimokawa, T., Kumar, M. V. & Lane, M. D. Effect of a fatty acid synthase inhibitor on food intake and expression of hypothalamic neuropeptides. Proc. Natl Acad. Sci. USA 99, 66–71 (2002).
Cha, S. H., Hu, Z., Chohnan, S. & Lane, M. D. Inhibition of hypothalamic fatty acid synthase triggers rapid activation of fatty acid oxidation in skeletal muscle. Proc. Natl Acad. Sci. USA 102, 14557–14562 (2005).
Li, L. et al. Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans. J. Hepatol. 64, 333–341 (2016).
Knobloch, M. et al. Metabolic control of adult neural stem cell activity by Fasn-dependent lipogenesis. Nature 493, 226–230 (2013). This study demonstrated that FASN is highly active in proliferating adult neural stem cell progenitors.
Bauer, D. E., Hatzivassiliou, G., Zhao, F., Andreadis, C. & Thompson, C. B. ATP citrate lyase is an important component of cell growth and transformation. Oncogene 24, 6314–6322 (2005).
Zaidi, N., Royaux, I., Swinnen, J. V. & Smans, K. ATP citrate lyase knockdown induces growth arrest and apoptosis through different cell- and environment-dependent mechanisms. Mol. Cancer Ther. 11, 1925–1935 (2012).
Wellen, K. E. et al. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 324, 1076–1080 (2009).
Schug, Z. T. et al. Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. Cancer Cell 27, 57–71 (2015).
Comerford, S. A. et al. Acetate dependence of tumors. Cell 159, 1591–1602 (2014).
Yoshii, Y. et al. Cytosolic acetyl-CoA synthetase affected tumor cell survival under hypoxia: the possible function in tumor acetyl-CoA/acetate metabolism. Cancer Sci. 100, 821–827 (2009).
Mashimo, T. et al. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell 159, 1603–1614 (2014).
Schug, Z. T., Vande Voorde, J. & Gottlieb, E. Metabolic fate of acetate in cancer. Nat. Rev. Cancer https://dx.doi.org/10.1038/nrc.2016.87 (2016).
Wang, C. et al. Acetyl-CoA carboxylase-α inhibitor TOFA induces human cancer cell apoptosis. Biochem. Biophys. Res. Commun. 385, 302–306 (2009).
Brusselmans, K., De Schrijver, E., Verhoeven, G. & Swinnen, J. V. RNA interference-mediated silencing of the acetyl-CoA-carboxylase-α gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res. 65, 6719–6725 (2005).
Chajes, V., Cambot, M., Moreau, K., Lenoir, G. M. & Joulin, V. Acetyl-CoA carboxylase α is essential to breast cancer cell survival. Cancer Res. 66, 5287–5294 (2006).
Jeon, S. M., Chandel, N. S. & Hay, N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 485, 661–665 (2012).
Griffiths, B. et al. Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth. Cancer Metab. 1, 3 (2013).
Williams, K. J. et al. An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicity. Cancer Res. 73, 2850–2862 (2013).
Young, R. M. et al. Dysregulated mTORC1 renders cells critically dependent on desaturated lipids for survival under tumor-like stress. Genes Dev. 27, 1115–1131 (2013). References 148–150 demonstrated that inhibition of FA desaturation leads to the induction of ER stress.
Sanchez-Alvarez, M. et al. Signaling networks converge on TORC1-SREBP activity to promote endoplasmic reticulum homeostasis. PLoS ONE 9, e101164 (2014).
Guo, D. et al. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci. Signal. 2, ra82 (2009).
Cheng, C. et al. Glucose-mediated N-glycosylation of SCAP is essential for SREBP-1 activation and tumor growth. Cancer Cell 28, 569–581 (2015). This study provided mechanistic evidence for SREBP activation in glycolytic cancer cells through enhanced glycosylation of SCAP. It also demonstrated that SCAP depletion reduces orthotopic glioblastoma growth.
Zelcer, N., Hong, C., Boyadjian, R. & Tontonoz, P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 325, 100–104 (2009).
Bovenga, F., Sabba, C. & Moschetta, A. Uncoupling nuclear receptor LXR and cholesterol metabolism in cancer. Cell Metab. 21, 517–526 (2015).
Guo, D. et al. An LXR agonist promotes GBM cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov. 1, 442–456 (2011).
Flaveny, C. A. et al. Broad anti-tumor activity of a small molecule that selectively targets the warburg effect and lipogenesis. Cancer Cell 28, 42–56 (2015). This study showed that inhibition of SREBP by an LXR antagonist blocks glycolysis and lipogenesis in cancer cells and inhibits tumour cell growth.
Kamisuki, S. et al. A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. Chem. Biol. 16, 882–892 (2009).
Li, X., Chen, Y. T., Hu, P. & Huang, W. C. Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling. Mol. Cancer Ther. 13, 855–866 (2014).
Li, X., Wu, J. B., Chung, L. W. & Huang, W. C. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations. Oncotarget 6, 41018–41032 (2015).
Tang, J. J. et al. Inhibition of SREBP by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques. Cell Metab. 13, 44–56 (2011).
Krol, S. K., Kielbus, M., Rivero-Muller, A. & Stepulak, A. Comprehensive review on betulin as a potent anticancer agent. Biomed. Res. Int. 2015, 584189 (2015).
Matsuda, M. et al. SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation. Genes Dev. 15, 1206–1216 (2001).
Winter, G. E. et al. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348, 1376–1381 (2015).
Marien, E. et al. Phospholipid profiling identifies acyl chain elongation as a ubiquitous trait and potential target for the treatment of lung squamous cell carcinoma. Oncotarget 7, 12582–12597 (2016).
Mason, P. et al. SCD1 inhibition causes cancer cell death by depleting mono-unsaturated fatty acids. PLoS ONE 7, e33823 (2012).
Hess, D., Chisholm, J. W. & Igal, R. A. Inhibition of stearoylCoA desaturase activity blocks cell cycle progression and induces programmed cell death in lung cancer cells. PLoS ONE 5, e11394 (2010).
Scaglia, N., Chisholm, J. W. & Igal, R. A. Inhibition of stearoylCoA desaturase-1 inactivates acetyl-CoA carboxylase and impairs proliferation in cancer cells: role of AMPK. PLoS ONE 4, e6812 (2009).
Roongta, U. V. et al. Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy. Mol. Cancer Res. 9, 1551–1561 (2011).
Fritz, V. et al. Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice. Mol. Cancer Ther. 9, 1740–1754 (2010).
Scaglia, N. & Igal, R. A. Inhibition of Stearoyl-CoA Desaturase 1 expression in human lung adenocarcinoma cells impairs tumorigenesis. Int. J. Oncol. 33, 839–850 (2008).
Budhu, A. et al. Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology 144, 1066–1075 (2013).
Singh, A. & Settleman, J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741–4751 (2010).
Menendez, J. A., Lupu, R. & Colomer, R. Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER-2/neu-overexpressing human breast cancer cells to docetaxel (taxotere). Breast Cancer Res. Treat. 84, 183–195 (2004).
Vazquez-Martin, A., Ropero, S., Brunet, J., Colomer, R. & Menendez, J. A. Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells. Oncol. Rep. 18, 973–980 (2007).
Liu, H., Liu, Y. & Zhang, J. T. A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction. Mol. Cancer Ther. 7, 263–270 (2008).
Ebos, J. M. & Kerbel, R. S. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 8, 210–221 (2011).
Sounni, N. E. et al. Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal. Cell Metab. 20, 280–294 (2014). This study suggested that inhibition of lipid synthesis may prevent disease progression following antiangiogenic therapy.
Golay, A., Swislocki, A. L., Chen, Y. D., Jaspan, J. B. & Reaven, G. M. Effect of obesity on ambient plasma glucose, free fatty acid, insulin, growth hormone, and glucagon concentrations. J. Clin. Endocrinol. Metab. 63, 481–484 (1986).
Lewis, D. Y. et al. Late imaging with [1-11C]Acetate improves detection of tumor fatty acid synthesis with PET. J. Nucl. Med. 55, 1144–1149 (2014).
DeGrado, T. R., Kitapci, M. T., Wang, S., Ying, J. & Lopaschuk, G. D. Validation of 18F-fluoro-4-thia-palmitate as a PET probe for myocardial fatty acid oxidation: effects of hypoxia and composition of exogenous fatty acids. J. Nucl. Med. 47, 173–181 (2006).
Krahmer, N., Guo, Y., Farese, R. V. Jr & Walther, T. C. SnapShot: lipid droplets. Cell 139, 1024–1024.e1 (2009).
Zechner, R. FAT FLUX: enzymes, regulators, and pathophysiology of intracellular lipolysis. EMBO Mol. Med. 7, 359–362 (2015).
Vamecq, J., Cherkaoui-Malki, M., Andreoletti, P. & Latruffe, N. The human peroxisome in health and disease: the story of an oddity becoming a vital organelle. Biochimie 98, 4–15 (2014).
Carling, D., Clarke, P. R., Zammit, V. A. & Hardie, D. G. Purification and characterization of the AMP-activated protein kinase. Copurification of acetyl-CoA carboxylase kinase and 3-hydroxy-3-methylglutaryl-CoA reductase kinase activities. Eur. J. Biochem. 186, 129–136 (1989).
Carracedo, A., Cantley, L. C. & Pandolfi, P. P. Cancer metabolism: fatty acid oxidation in the limelight. Nat. Rev. Cancer 13, 227–232 (2013).
Zaugg, K. et al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev. 25, 1041–1051 (2011).
Park, J. H. et al. Fatty acid oxidation-driven src links mitochondrial energy reprogramming and oncogenic properties in triple-negative breast cancer. Cell Rep. 14, 2154–2165 (2016).
Szutowicz, A., Kwiatkowski, J. & Angielski, S. Lipogenetic and glycolytic enzyme activities in carcinoma and nonmalignant diseases of the human breast. Br. J. Cancer 39, 681–687 (1979).
Hietanen, E., Punnonen, K., Punnonen, R. & Auvinen, O. Fatty acid composition of phospholipids and neutral lipids and lipid peroxidation in human breast cancer and lipoma tissue. Carcinogenesis 7, 1965–1969 (1986).
Yokoyama, C. et al. SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell 75, 187–197 (1993).
Hua, X. et al. SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element. Proc. Natl Acad. Sci. USA 90, 11603–11607 (1993).
Tontonoz, P., Kim, J. B., Graves, R. A. & Spiegelman, B. M. ADD1: a novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation. Mol. Cell. Biol. 13, 4753–4759 (1993).
Bennett, M. K., Lopez, J. M., Sanchez, H. B. & Osborne, T. F. Sterol regulation of fatty acid synthase promoter. Coordinate feedback regulation of two major lipid pathways. J. Biol. Chem. 270, 25578–25583 (1995).
Swinnen, J. V., Esquenet, M., Goossens, K., Heyns, W. & Verhoeven, G. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Cancer Res. 57, 1086–1090 (1997).
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
US National Library of Medicine. ClinicalTrials.govhttps://clinicaltrials.gov/ct2/show/NCT02223247 (2014).
Buckley, D., Heuer, T., O'Farrell, M., McCulloch, B. & Kemble, G. Translational studies of a first-in-class FASN Inhibitor, TVB-2640, linking preclinical studies to clinical laboratory observations in solid tumor patients. Mol. Cancer Res. 14 (Suppl. 1), Abstr. A75 (2016).
Shaw, G. et al. Therapeutic fatty acid synthase inhibition in prostate cancer and the use of 11c-acetate to monitor therapeutic effects. J. Urol. 189, E208–E209 (2013).
Zhou, W. et al. Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells. Cancer Res. 67, 2964–2971 (2007).
Orita, H. et al. Selective inhibition of fatty acid synthase for lung cancer treatment. Clin. Cancer Res. 13, 7139–7145 (2007).
El Meskini, R. et al. Fatty acid synthase inhibition for ovarian cancer. Cancer Res. 68, Supplement 5667 http://cancerres.aacrjournals.org/content/68/9_Supplement/5667 (2008).
Orita, H. et al. Inhibition of fatty acid synthase by C247 for lung cancer treatment. Cancer Res. 65, Supplement 2380 http://cancerres.aacrjournals.org/content/65/9_Supplement/558.2 (2005).
Pizer, E. S. et al. Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res. 56, 2745–2747 (1996).
Kridel, S. J., Axelrod, F., Rozenkrantz, N. & Smith, J. W. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 64, 2070–2075 (2004).
Carvalho, M. A. et al. Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model. Int. J. Cancer 123, 2557–2565 (2008).
Sadowski, M. C. et al. The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate cancer. Oncotarget 5, 9362–9381 (2014).
Lee, H. R., Hwang, K. A., Nam, K. H., Kim, H. C. & Choi, K. C. Progression of breast cancer cells was enhanced by endocrine-disrupting chemicals, triclosan and octylphenol, via an estrogen receptor-dependent signaling pathway in cellular and mouse xenograft models. Chem. Res. Toxicol. 27, 834–842 (2014).
Beckers, A. et al. Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res. 67, 8180–8187 (2007).
Samudio, I. et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J. Clin. Invest. 120, 142–156 (2010).
Tirado-Velez, J. M., Joumady, I., Saez-Benito, A., Cozar-Castellano, I. & Perdomo, G. Inhibition of fatty acid metabolism reduces human myeloma cells proliferation. PLoS ONE 7, e46484 (2012).
Liu, P. P. et al. Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline. Oncogene https://dx.doi.org/10.1038/onc.2016.103 (2016).
Von Roemeling, C. A. et al. Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Clin. Cancer Res. 19, 2368–2380 (2013).
The authors thank B. Peck for helpful discussions and all members of the Schulze laboratory for critical reading of the manuscript. We also wish to apologize for the numerous important studies in the field of lipid metabolism in cancer that we could not cite owing to space limitations.
The authors declare no competing financial interests.
- Fatty acid synthase
(FASN). Mammalian FASN is a multifunctional enzyme containing seven catalytic domains: malonyl/acetyltransferase, β-ketoacyl-synthase, dehydrase, enoyl-ACP-reductase, β-ketoacyl-reductase, thioesterase and acyl carrier protein.
The process by which fatty acids are sequentially degraded to acetyl-CoA, which can subsequently be oxidized by the mitochondrial tricarboxylic acid cycle to produce ATP.
- E-Box sequences
Palindromic DNA element with the consensus sequence CANNTG, which is found in the promoters of many genes and mediates transcription factor binding.
- Lipid droplets
Specialized organelles rich in neutral lipids, cholesterol and cholesteryl esters.
- Lipid rafts
Highly specialized microdomains in the plasma membrane characterized by distinct lipid composition that act as platforms for the assembly of signalling molecules.
- Raman spectroscopy
A label-free spectroscopic imaging technique that can be applied to tissue sections. It is based on a characteristic shift in the frequency of light used to illuminate a specimen.
Wasting syndrome characterized by atrophy of muscle and adipose tissue and extreme weight loss.
Post-translational covalent attachment of fatty acids to amino acid side-chains of proteins. Common examples are myristoylation and palmitoylation to promote membrane association of proteins.
- WNT proteins
A family of secreted glycoproteins involved in tissue homeostasis and organ development. One pathway activated by WNT proteins is β-catenin-induced transcription.
- Epithelial-to-mesenchymal transition
(EMT). A phenotype that occurs during development as well as in cancer cells. During EMT, epithelial cells acquire mesenchymal traits, including loss of cell–cell contacts and enhanced motility, caused by altered transcription and microRNA regulation of cytoskeletal proteins.
- Non-alcoholic fatty liver disease
(NAFLD). Pathological accumulation of fat in the liver often associated with insulin resistance and the metabolic syndrome.
- Metronomic treatment regimens
Therapeutic concept describing the continuous administration of drugs at doses below the maximum tolerated dose.
- Unfolded protein response (UPR) pathway
A stress response pathway activated upon accumulation of misfolded proteins in the lumen of the endoplasmic reticulum.
- Imaging mass spectrometry
(IMS). Technique to visualize the spatial distribution of metabolites, biomarkers or proteins in a biological sample, such as a tissue section.
About this article
Cite this article
Röhrig, F., Schulze, A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer 16, 732–749 (2016). https://doi.org/10.1038/nrc.2016.89
Cancer Letters (2021)
Cancer Letters (2021)
Loss of mitochondrial aconitase promotes colorectal cancer progression via SCD1-mediated lipid remodeling
Molecular Metabolism (2021)
Molecular Metabolism (2021)
Cancer Letters (2021)